IL4 and prostate carcinoma: In keeping with our results that suggest a probable protective effect of the rs2243250 variant against tumor development, it has been reported that in prostate cancer, the IL-4 5′ variant of promoter sequence, rs2243250 decreases IL-4 activity [41].